Recently, we have found that TMEM16A is overexpressed in human breast cancer samples, and TMEM16A overexpression is associated with good prognosis in PR-positive or HER2-negative breast cancer patients following tamoxifen treatment, especially in those patients with the low expression of Ki67 [43, 95]. This evidence concerns the gene MKI67 and breast cancer.